<DOC>
	<DOCNO>NCT01362712</DOCNO>
	<brief_summary>This trial first trial IP , [ F-18 ] CP-18 , conduct exploratory Phase I trial design collect information IP administer evaluate first time human . The trial evaluate safety , biodistribution dosimetry data normal subject trial evaluate safety , biodistribution tumor background image data , correlate image data caspase 3 activity level surgical specimen analyze immunohistochemistry cancer subject . All study result evaluate analyzed order consider design future clinical trial . The information collect exploratory , Phase I study use diagnostic purpose , ass subject 's response therapy , clinical management subject .</brief_summary>
	<brief_title>Exploratory , Phase I , Open Label , Non-randomized Study F18CP-18 PET Normal Breast Cancer Subjects</brief_title>
	<detailed_description>The Sponsor intend conduct exploratory investigation [ F-18 ] CP-18 human subject . In study [ F-18 ] CP-18 , intend assess biodistribution , PET scan resolution , signal background ratio tumor , adverse event . This exploratory Phase I study use obtain necessary safety dosimetry data normal subject collect drug biodistribution data , tumor background image data breast cancer subject . The information collect study use diagnostic purpose , ass subject 's response therapy , clinical management subject .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>For Normal Volunteers Subject female male race / ethnicity 21 75 year old time investigational product administration Subject subject 's legally acceptable representative provide write informed consent Subject capable complying study procedure Subject must renal function value define laboratory result within follow range : Serum creatinine ≤ 2x institutional upper limit normal For Cancer Patients Patient female male race / ethnicity 21 75 year old time investigational product administration Patients subject 's legally acceptable representative provide write informed consent Patient capable comply study procedure Patient must renal function value define laboratory result within follow range : Serum creatinine ≤ 2x institutional upper limit normal BUN &lt; 2X institutional upper limit normal Patient must confirm diagnosis stage IIB/IIIA/IIIB , locally advanced breast cancer Patient schedule surgical resection tumor ( ) undergo neoadjuvant treatment within approximately 7 day follow [ F18 ] CP18 PET/CT scan Patient adequate size breast tumor ( ≥1.0 cm ) amenable image Patient 's tumor tissue obtainable follow surgery order perform immunohistochemistry stain use caspase 3 and/or apoptosis biomarkers Patient must previous baseline ( preneoadjuvant treatment ) diagnostic image exam include limited MRI , CT , mammography , [ F18 ] FDG PET/CT scan identifies breast tumor location For Normal Volunteers Subject nursing Subject pregnant Subject involve investigative , radioactive research procedure within past 14 day Subject condition personal circumstance , judgment investigator , might interfere collection complete data data quality For Cancer Patients Subject nursing Subject pregnant Subject involve investigative , radioactive research procedure within past 14 day Subject condition personal circumstance , judgment investigator , might interfere collection complete data data quality Patient tumor tissue ( ) obtainable tumor resection caspase 3 and/or biomarker immunohistochemistry assay Patient treatment intervention ( ) [ F18 ] CP18 PET/CT scan tumor resection Patient history current evidence condition , therapy , lab abnormality , opinion study investigator treat physician might confound result study pose additional risk patient participation study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>radiation</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>[ F-18 ]</keyword>
</DOC>